换一批Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study.
第一作者：
David,Slade
第一单位：
US Medical Affairs, GSK, Research Triangle Park, NC, USA.
作者：
医学主题词
投药, 吸入(Administration, Inhalation);肾上腺皮质激素类(Adrenal Cortex Hormones);肾上腺素能β-2受体激动剂(Adrenergic beta-2 Receptor Agonists);老年人(Aged);老年人, 80以上(Aged, 80 and over);苄醇类(Benzyl Alcohols);支气管扩张药(Bronchodilator Agents);氯苯类(Chlorobenzenes);数据库, 事实型(Databases, Factual);复方合剂(Drug Combinations);女(雌)性(Female);人类(Humans);Kaplan-Meiers评估(Kaplan-Meier Estimate);Logistic模型(Logistic Models);男(雄)性(Male);服药依从性(Medication Adherence);中年人(Middle Aged);毒蕈碱拮抗剂(Muscarinic Antagonists);倾向性评分(Propensity Score);肺疾病, 慢性阻塞性(Pulmonary Disease, Chronic Obstructive);奎宁环类(Quinuclidines);回顾性研究(Retrospective Studies);美国(United States)
DOI
10.1186/s12890-021-01612-5
PMID
34332555
发布时间
2024-08-13
- 浏览0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
